It is my understanding that Bulk Sales of API have very little margin associated with it. You can see this from the Q2 results. I agree that eventually you can estimate Royalty revenues by using these Sales figures once things get rolling. All in All a good call with excellent progress. Would like to see another Partner come along on the SubQ side or more clarity on new targets from Roche and Pfizer. Expect stock stick around this price for a while.
News 
Market Data 
Discover 
